LatigoBiotherapeutics
Clinical-stage biopharma developing NaV1.8-selective, non-opioid analgesics — Nasdaq-listed August 2026 as the best-funded second mover behind Vertex’s Journavx
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered at 1300 Rancho Conejo Blvd, Suite 305, Thousand Oaks, California. Rather than emerging from an individual founder’s lab or garage, Latigo is a venture-built asset: it was created and incubated inside biotech-focused venture firm Westlake Village BioPartners. That governance structure — venture-firm-as-founder rather than founder-CEO — is a material starting point for underwriting the name, as capital formation, board composition, and management succession have all been shaped by the incubator relationship rather than founder control.
Farzan brings more than two decades of biopharmaceutical leadership and was recruited as Latigo’s first full-time CEO. He previously served as CEO of precision-oncology company Kinnate Biopharma, which he joined in 2020 and built to the point of advancing three internally discovered compounds into the clinic. He led Kinnate’s $270 million IPO and its subsequent sale to Xoma Corporation in April 2024 — a complete fundraising-to-exit cycle directly relevant to Latigo’s own path. Earlier in his career he spent seven years at PaxVax, most recently as President and CEO. Farzan succeeded Desmond Padhi, who had served as interim CEO through the stealth period; the board’s stated rationale for the appointment centered on pairing capital-markets execution experience with clinical-development depth.
Spent 16 years at Amgen, latterly heading R&D, before co-founding Westlake Village BioPartners with Beth Seidenberg in 2018. Led Latigo’s incubation and architected its early capital structure, including the Series A.
A clinical-development specialist who spent 19 years at Amgen across pharmacokinetics and other functions. Co-conceived the pain-company thesis with Harper in 2019 and steered clinical strategy as interim CEO through stealth before handing off to Farzan.
Latigo exited stealth in February 2024 alongside a $135 million Series A, with board chair duties held by Nancy Stagliano, Ph.D., CEO of neuro-immune startup Neuron23. The company subsequently strengthened its capital-markets-facing bench in September 2024 with the appointment of CFO Tim Lugo and the addition of venture veterans Beth Seidenberg and Jim Tananbaum to the board — a build-out that culminated in the August 2026 Nasdaq listing.
Latigo runs an in-house discovery engine that pairs human-genetics-validated targets with AI/machine-learning and structure-based design to generate oral, small-molecule NaV1.8 inhibitors — a mechanism designed to block pain signal transmission at its source without the addiction liability of opioids. The company remains pre-revenue and pre-approval. Ahead of the IPO it reported 59 full-time employees and a cash balance of $54.8 million as of June 30, 2026.
An oral, selective NaV1.8 inhibitor that received FDA Fast Track designation in March 2025. In a 343-patient Phase 2b trial in the abdominoplasty (moderate-to-severe acute postoperative pain) model, the compound met its primary endpoint and key secondary endpoints, with results published as an original research article in NEJM in July 2026. A second confirmatory trial in a bunionectomy model is planned to support a future NDA filing alongside the abdominoplasty data.
A structurally distinct, second NaV1.8 inhibitor now in Phase II for chronic musculoskeletal pain. A portion of IPO proceeds is earmarked to carry this asset through Phase II proof-of-concept and into Phase III.
An earlier-stage NaV1.8 candidate in preclinical development. Alongside LTG-001 and LTG-321, it rounds out a single-target, multi-asset pipeline structure that provides indication-expansion optionality and backup-molecule coverage.
LTG-001 Phase 2b headline figures (secondary-source reporting — primary-source quantitative detail unverified): Trade-press coverage indicates that high-dose LTG-001 achieved an SPID48 (summed pain-intensity difference over 48 hours) of 62.1, ahead of the 40.86 recorded by the active comparator hydrocodone/acetaminophen (Vicodin), and that 52% of high-dose patients remained opioid-free during treatment versus 22% on placebo. These figures come from secondary analyst outlets (e.g., PRISM MarketView) rather than the NEJM article itself; the primary source we retrieved (NEJM, Vol. 395, Issue 5, published July 30, 2026) confirms only that LTG-001 produced statistically significant pain reduction versus placebo over 48 hours, without the specific SPID48/opioid-sparing figures in the text we accessed. We would recommend cross-checking these numbers against the full NEJM article and company IR materials before relying on them for valuation work.
Discovery platform: Latigo’s core differentiator is an integrated in-house engine that layers AI/ML-driven design, structure-based design, and knowledge-based design on top of human-genetics target validation to optimize potency and selectivity. Lead compound LTG-001 is reported to carry greater than 600-fold selectivity for NaV1.8 over other sodium channel subtypes, with no central-nervous-system exposure cited as the key differentiating safety rationale — a peripherally restricted pharmacologic profile consistent with the class’s addiction-avoidance thesis.
Since exiting stealth in February 2024, Latigo has raised $285 million across two private rounds, and added a further $345.6 million via its August 2026 IPO — taking cumulative capital raised through listing to more than $630 million. Early rounds were anchored by incubator Westlake Village BioPartners alongside specialist healthcare VCs; from Series B onward, larger crossover and institutional capital — Blue Owl Capital, the Qatar Investment Authority — entered the cap table, a fairly conventional pre-IPO capital-formation arc for a well-sponsored clinical-stage name.
Incubator Westlake Village BioPartners led the round, with 5AM Ventures and Foresite Capital as co-leads and Corner Ventures participating. LTG-001 had already entered a Phase 1 trial in healthy volunteers at the time of the raise; proceeds were directed toward accelerating clinical development and further building out the discovery engine.
Alternative-asset manager Blue Owl Capital stepped in as lead investor, joined by healthcare-focused crossover funds Deep Track Capital and Cormorant Asset Management, strategic investor Sanofi Ventures, and the Qatar Investment Authority. Blue Owl’s Kevin Raidy joined the board, formalizing pre-IPO governance. LTG-001 received FDA Fast Track designation around the same period.
Pricing path: Terms filed August 3, 2026 called for 16 million shares at a $16–18 range, implying a fully diluted valuation of roughly $1.2 billion at the midpoint. Following the NEJM publication, investor demand firmed and the deal was upsized on August 6 to 19.2 million shares, pricing at the top of the range at $18.00 for gross proceeds of $345.6 million. Underwriters hold a 30-day option on up to an additional 2.88 million shares (greenshoe). First trade was August 7, with closing scheduled for August 10.
Underwriting syndicate: Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities served as joint book-running managers.
Data note: Given the upsized share count and top-of-range pricing, the final fully diluted post-IPO market value is almost certainly above the $1.2 billion figure disclosed at the original range’s midpoint; we did not identify an officially confirmed fully diluted valuation reflecting the upsized deal as of this writing.
The NaV1.8 inhibitor class achieved clinical and commercial proof of concept with the January 2025 FDA approval of Vertex Pharmaceuticals’ Journavx (suzetrigine). Latigo enters as a well-capitalized but later mover, competing against SiteOne Therapeutics (acquired by Eli Lilly in May 2025 for up to $1 billion) and Jiangsu Hengrui Medicine (HRS-4800, Phase II), among others. The company differentiates on pipeline breadth, data quality, and management track record, but Vertex’s commercial head start and the inherent execution risk of a clinical-stage name are equally material to the underwriting case and are presented alongside the advantages below.
An integrated in-house platform that layers AI/ML and structure-based design onto human-genetics-validated targets has produced three structurally distinct NaV1.8 candidates (LTG-001, LTG-321, LTG-418) from a single internal engine. Relative to single-asset competitors, this gives Latigo a degree of pipeline risk diversification that a one-shot rival lacks.
LTG-001’s Phase 2b results represent only the second original-research NEJM article on an acute-pain drug in the past 15 years. Clearing peer review at a top-tier journal is a strong external validation of data quality and can be leveraged in FDA discussions and Phase 3 design justification.
CEO Nima Farzan led Kinnate Biopharma through a $270 million IPO and a subsequent sale to Xoma — a complete public-market cycle directly transferable to Latigo. The board includes Amgen-pedigreed venture veterans Beth Seidenberg and Jim Tananbaum, and Westlake Village BioPartners’ incubation track record adds a further layer of credibility.
Private rounds already drew large, strategically relevant backers — Blue Owl Capital, Sanofi Ventures, the Qatar Investment Authority — and the top-of-range, upsized $345.6 million IPO provides a capital runway intended to fund Phase 3 development on the lead asset and Phase II completion on the second.
Journavx logged more than 550,000 prescriptions and $60 million in revenue in 2025 following its January 2025 approval, with coverage extended to over 200 million commercial and government lives by January 2026 and access secured across all three national PBMs. Latigo starts from a structural disadvantage on commercial infrastructure, real-world prescribing data, and payer leverage relative to an incumbent with that head start.
The pivotal-quality data secured to date rests on one Phase 2b trial in a single pain model (abdominoplasty); the planned confirmatory trial in a bunionectomy model has not yet reported. Clinical and regulatory risk persists through Phase 3 and NDA submission, and the company remains exposed to the trial-failure risk endemic to clinical-stage biotech.
Eli Lilly’s up-to-$1 billion acquisition of SiteOne Therapeutics (STC-004) and Jiangsu Hengrui Medicine’s HRS-4800 both bring large-pharma capital and R&D infrastructure to bear on NaV1.8 and adjacent targets. Class-wide clinical or commercial setbacks elsewhere in the category could weigh on Latigo’s valuation independent of its own execution.
With a cash balance of just $54.8 million heading into the IPO, even including this raise, funding two Phase 3 programs (acute and chronic pain) through to NDA submission will likely require additional equity capital — a real prospect for dilution to current shareholders down the line.
Data-integrity note: Certain clinical quantitative figures cited in this report (SPID48, opioid-sparing rate) and the post-IPO fully diluted market value are drawn in part from secondary media coverage rather than the company’s official disclosures or SEC filings. We would recommend verifying these figures against Latigo’s S-1/424B registration statements, the full NEJM article, and company IR materials before relying on them for investment decisions.